Immune checkpoint inhibitors and the clinical management of immune-related toxicities

Immune checkpoint inhibitors have expanded the treatment of solid and hematologic malignancies, but the same release of inhibitory T-cell signaling can provoke inflammatory injury in almost any organ. This narrative critical review examines how immune-related adverse events should be recognized, differentiated from competing diagnoses, treated, and monitored without neglecting oncologic benefit. PubMed/MEDLINE-indexed evidence and clinical guidance from major oncology and organ-specific societies were examined in 2026, with emphasis on comparative studies, observational cohorts, systematic reviews, and practice guidelines. Toxicity patterns depend on checkpoint target, treatment combination, host characteristics, and affected tissue; severity alone does not determine urgency. Cutaneous eruptions and thyroid dysfunction commonly permit conservative treatment, whereas colitis, pneumonitis, hepatitis, myocarditis, and neuromuscular syndromes demand phenotype-specific investigation and timely escalation. Corticosteroids remain central for many moderate or severe events, but endocrine deficiencies usually require hormone replacement, and selected steroid-refractory conditions benefit from targeted immunomodulation. The available evidence for second-line agents and immunotherapy rechallenge is predominantly nonrandomized. Effective manage ment therefore requires early detection, exclusion of infection and other mimics, specialist coordination, individualized risk assessment, and long-term surveillance for persistent or delayed toxicity.